AZD9773

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Septic ShockSevere Sepsis

Phase 2

A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

CompletedNCT01144624

AstraZenecaSeptic Shock, Severe Sepsis

Start: 2010-07-31End: 2011-08-31Updated: 2014-10-06

A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

CompletedNCT01145560

AstraZenecaSeptic Shock, Severe Sepsis

Start: 2010-10-31End: 2012-05-31Updated: 2014-10-06

Related Papers

A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock.

2013-05-1712 citations

Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-α polyclonal fragment antibody AZD9773 in patients with severe sepsis.

2012-09-233 citations